GSK Halts Development Of Vertex’ Brecanavir Due To Formulation Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
The investigational protease inhibitor was in Phase II development for the treatment of HIV.
You may also be interested in...
Vertex Hopes To PROVE Telaprevir’s Promise With Final Installment Of Phase II Program
Company plans to begin Phase III in the second half of 2007; further protocol discussions with FDA are planned for mid-2007.
Vertex Hopes To PROVE Telaprevir’s Promise With Final Installment Of Phase II Program
Company plans to begin Phase III in the second half of 2007; further protocol discussions with FDA are planned for mid-2007.
GSK Reorganized R&D Structure Will Highlight Late-Stage Development
The firm plans to move eight agents into Phase III clinical trials in 2006.